Home � Products & Services � Benchmarking Reports � Medical Affairs

Best Practices in Utilizing Health Outcomes Data

Download FREE Excerpt

ID: PSM-236

Features:

10 Info Graphics

28 Data Graphics

174 Metrics

9 Narratives

5 Best Practices

Pages: 51

Published: Pre-2019

Delivery Format: Shipped

License Options:
$4000 - 1 user
$12000 - Up to 5 users
$20000 - Up to 20 users

Buy Now

Buy this research as part of a

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

Optimizing the use of Health Outcomes data is vital to the success of biotechnology and pharmaceutical companies. This report provides insight and best practices that are being used by companies and reviews the use of Health Outcomes data in promotional/commercial settings and the possible Regulatory issues that arise as a result of their use.

This report identifies how companies continue to navigate using prospective and retrospective Health Outcomes data in on-label and off-label instances. It gives insight into how companies are actively utilizing data that is critical to the success of drugs and achieving beneficial formulary status.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Manufacturing; Biotech; Consumer Products; Consulting

Companies Profiled:
Abbott; Alfred Mann Foundation; ASSESSmint; Baxter; Bayer; Becton Dickinson; C. Kalb & Associates; LLC; Eisai Inc; Laboratorios Esteve; Mahde Taban; Medtronic; Novo Nordisk A/S; Pfizer; Regeneron Pharmaceuticals; Shire

Study Snapshot

The benchmark class includes 18 participants from 16 companies across the pharmaceutical, biotech and medical device industries. The key topics covered in this research include:

Structure and Reporting Lines of Authority
Health Outcomes Decisions
Use of Health Outcomes Data Proactively and Retrospectively
Who and How is Health Outcomes Data Utilized with Different Groups
Health Outcomes Review Process and Structure

Sample Key Findings

Health Outcomes Function Continues to Sit Within a Centralized Organization: Although no structure is perfect, still 6 out of 10 companies place their Health Outcomes Group as part of a centralized organization. In 9 out of 10 benchmark companies, the Health Outcomes Function is led by senior level employees.

Health Outcomes Continue to Remain Conservative in its Review Approach: All companies tend to have their Health Outcomes data reviewed by groups that include Medical Affairs, Legal and Regulatory, with some input from the Commercial/Marketing groups. For the most part, companies remain consistent in their approach to reviewing data that could be used for promotional purposes.
Pharmaceutical Companies Choose to Review Health Outcomes Data at Brand Level: Three-Fourths of the benchmark class organizations review Health Outcomes data at brand level. As compared to 2011, brand level review of data has increased by 23% from 2009.

Table of Contents

INTRODUCTION 5
SUMMARY OF KEY INSIGHTS 7
KEY FINDINGS 8
UNIVERSE OF LEARNING 10
HEALTH OUTCOMES REPORTING STRUCTURE 13
Structure of Health Outcomes Function 14
Health Outcomes Leadership Growing in Seniority 15
More HO Groups Report to S&M than in 2009 16
UTILIZING HEALTH OUTCOME DATA 17
Most Common Decisions Made By Health Outcomes 18
About 60 Percent Use Health Outcomes Data for Unsolicited and Proactive Requests 19
How Companies Provide HO Data When They Offer Unsolicited and Proactive 20
Health Outcomes Data Used Most Often with Managed Care Account
Managers and Medical Science Liaisons 21
Almost All Companies Use Prospective Health Outcomes Data for
Promotional Purposes 22
Variance Exists in Corporate Usage of Prospective Health Outcomes Data 23
Retrospective Use of HO Data Remains Cautious 24
Companies More Likely to Use Retrospective Health Outcomes Data
Off-Label than in 2009 25
Managed Care Account Managers Are Provided Data Most Often for
On-Label Purposes 26
Health Outcomes Data Used More Often With Sales Reps Than in 2009,
Typically On-Label When Utilized 27
Medical Science Liaisons Receive a Mix of Health Outcomes Data, More
so Than Others 28
Brand Teams Receive Data Frequently for On-Label Purposes, and
Off-Label Has Risen As Well 29
Sales Training Receives Health Outcomes Data On-Label, But Less
Frequently Than Other Groups 30
About 50% Avoid Health Outcomes Data for Off-Label Purposes 31
Health Outcomes Data Is Used in a Limited Manner with Other Groups 32
HEALTH OUTCOME DATA REVIEW PROCESS 33
Medical, Legal and Commercial Reviews Are the Groups that Often
Examine Health Outcomes Data 34
Medical, Legal and Regulatory Consistently Sit on Health Outcomes Review Committee 35
Health Outcomes Data Reviewed Most Often at Brand Level 36
HEALTH OUTCOME DATA OVERVIEW 37
Tiered Classifications Not Being Implemented By Health Outcomes Groups 38
Most Companies See a High Level of Risk With Health Outcomes Data
For Off-Label Promotion 39
Utilization of Health Outcome Data 40-41
Strategic Planning A Critical Output From Internal Health Outcomes Data
Usage 42
Treatment Guidelines Top Use of Health Outcomes Data with Physicians 43
Reimbursement and Drug Formulary Inclusion Most Used Activities with
Health Outcomes Data Usage 44
Patients Not Seen As a Vital When It Comes to Health Outcomes Data 45
Process Flow for using Health Outcomes Data for Promotional/ Commercial Purposes 46
HEALTH OUTCOME DATA BEST PRACTICES INSIGHTS 47
Major Initiatives 48
Best Practices for Utilizing Health Outcome 49
Primary Elements in Health Outcomes Piece 50
ABOUT BEST PRACTICES, LLC 51